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A bs tr ac t
Background
The use of inhaled glucocorticoids for persistent asthma causes a temporary reduction 
in growth velocity in prepubertal children. The resulting decrease in attained height 
1 to 4 years after the initiation of inhaled glucocorticoids is thought not to decrease 
attained adult height.
Methods
We measured adult height in 943 of 1041 participants (90.6%) in the Childhood 
Asthma Management Program; adult height was determined at a mean (±SD) age of 
24.9±2.7 years. Starting at the age of 5 to 13 years, the participants had been randomly 
assigned to receive 400 μg of budesonide, 16 mg of nedocromil, or placebo daily 
for 4 to 6 years. We calculated differences in adult height for each active treatment 
group, as compared with placebo, using multiple linear regression with adjustment 
for demographic characteristics, asthma features, and height at trial entry.
Results
Mean adult height was 1.2 cm lower (95% confidence interval [CI], −1.9 to −0.5) in 
the budesonide group than in the placebo group (P = 0.001) and was 0.2 cm lower 
(95% CI, −0.9 to 0.5) in the nedocromil group than in the placebo group (P = 0.61). 
A larger daily dose of inhaled glucocorticoid in the first 2 years was associated with 
a lower adult height (−0.1 cm for each microgram per kilogram of body weight) 
(P = 0.007). The reduction in adult height in the budesonide group as compared with 
the placebo group was similar to that seen after 2 years of treatment (−1.3 cm; 95% CI, 
−1.7 to −0.9). During the first 2 years, decreased growth velocity in the budesonide 
group occurred primarily in prepubertal participants.
Conclusions
The initial decrease in attained height associated with the use of inhaled gluco-
corticoids in prepubertal children persisted as a reduction in adult height, although 
the decrease was not progressive or cumulative. (Funded by the National Heart, 
Lung, and Blood Institute and the National Center for Research Resources; CAMP 
ClinicalTrials.gov number, NCT00000575.)
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Inhaled glucocorticoids are the rec-ommended therapy for persistent asthma in children.1 In prepubertal children, however, 
the use of inhaled glucocorticoids has been 
shown to reduce growth velocity, resulting in a 
linear growth reduction of 0.5 to 3.0 cm (approx-
imately 1 cm on average) during the first few 
years of therapy.2-4 This reduction has been re-
ported for low-to-medium doses, but the degree 
of reduction is dependent on the type of inhaled 
glucocorticoid and the delivery method.5-9
Although growth velocity returns to normal 
within a few years after the initiation of inhaled 
glucocorticoid therapy (resulting in a deficit in 
height that is not progressive), the long-term ef-
fect of the initial decrease in growth velocity on 
attainment of adult height is still unclear.10-12 
Retrospective, cross-sectional studies of the ef-
fect of inhaled glucocorticoid therapy in child-
hood on the attainment of adult height have had 
conflicting results.10,13-15 In one small longitudi-
nal study,11 there was no significant difference 
between actual adult height and predicted adult 
height in 142 participants who had received 
budesonide in variable daily doses (mean, 427 μg) 
during childhood for a mean of 9.2 years.
At the end of the Childhood Asthma Manage-
ment Program (CAMP) clinical trial, we predicted 
that the children receiving budesonide (Pulmicort 
Turbuhaler, AstraZeneca) for a mean follow-up 
of 4.3 years would attain the same adult height 
as the children receiving nedocromil (Tilade, 
Rhone-Poulenc Rorer) or placebo.2 It has been 
hypothesized that children receiving inhaled 
glucocorticoids grow for a longer period of time, 
eventually catching up and having no long-term 
effects from the decreased growth velocity seen 
in the first few years of therapy.16 Thus, the ef-
fect of inhaled glucocorticoids on height has 
often been characterized as growth retardation 
rather than growth suppression. We later re-
ported that the heights of the participants in the 
budesonide group had not caught up with the 
heights of participants in the placebo group af-
ter an additional 4.8 years of follow-up (total, 9.1 
years), until the ages of 12 to 23 years.12 The 
purpose of the current study was to continue the 
height follow-up of the CAMP participants to 
assess the effects of budesonide and nedocromil 
on adult height.
Me thods
Participants and Study Design
From December 1993 through September 1995, 
we randomly assigned 1041 children between the 
ages of 5 and 13 years with mild-to-moderate 
asthma to one of three study groups in the dou-
ble-blind, placebo-controlled CAMP trial. In this 
study, we compared the efficacy and safety of 
200 μg of budesonide administered by means of 
a dry-powder inhaler twice daily (400 μg per 
day), 8 mg of nedocromil administered by means 
of a metered-dose inhaler twice daily (16 mg per 
day), and placebo. Albuterol was used for asthma 
symptoms in all three groups. The design, meth-
ods, and results of the trial have been described 
previously.2,17 At the end of the trial (mean follow-
up, 4.3 years), the children were recruited into an 
observational cohort, as described previously.12 
During follow-up, the children were treated for 
asthma by their primary care physicians under 
advisement from the CAMP physicians on the ba-
sis of the guidelines of the National Asthma Edu-
cation and Prevention Program.1 Height and weight 
were measured every 6 months during the ini-
tial 4.5 years of observational follow-up and 1 to 
2 times a year during the next 8 years. Adult height 
was determined at a mean (±SD) age of 24.9±2.7 
years. Tanner staging was performed annually 
until the participants were 18 years of age or at-
tained sexual maturity. (For details regarding the 
trial design and phases of the observational fol-
low-up, see Fig. S1 in the Supplementary Appen-
dix, available with the full text of this article at 
NEJM.org.) All study phases were approved by 
the institutional review board at each study cen-
ter. Participants who were 18 years of age or 
older provided written informed consent; those 
under the age of 18 years provided assent, with 
written informed consent provided by their par-
ents or guardians.
At each clinic visit, a trained technician used 
a stadiometer (Harpenden 603, Holtain) to mea-
sure height, as described in the protocol (available 
at NEJM.org), and investigators obtained an in-
terim history of participants’ health and medica-
tion use. During the first 8 years of follow-up, 
this information was supplemented with infor-
mation obtained during telephone contacts that 
were evenly spaced around the clinic visits.
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On the basis of reported recommendations,18-21 
adult height was defined as either the mean of all 
measurements performed at the age of 18 years 
or older for women and at the age of 20 years or 
older for men or, if height was not measured at 
these ages, the most recently obtained height 
that was less than 1 cm greater than a height 
obtained at least 1 year previously.
Statistical Analysis
We used a multiple linear regression model to com-
pare mean height in the budesonide and nedocro-
mil groups with that in the placebo group, with 
adjustment for eight covariates at trial entry: age, 
race or ethnic group, sex, clinic, height, duration 
of asthma (<3 years, ≥3 to <7 years, or ≥7 years), 
severity of asthma (moderate or mild), and pres-
ence or absence of skin-test reactivity. Data for 
each participant were analyzed in the study group 
to which the participant had been randomly as-
signed, regardless of subsequent asthma treat-
ment. The adjusted mean height in each study 
group was computed from the regression model 
at the mean values for the covariates.22 To assess 
the statistical significance of potential variations 
in height differences between the budesonide or 
nedocromil group and the placebo group across 
subgroups defined by race or ethnic group, age at 
trial entry, and duration of asthma at entry, we 
added covariate interaction terms to the regres-
sion model. Although these post hoc interaction 
tests may have a low statistical power for detect-
ing variations in height effects across subgroups, 
we wanted to examine the qualitative consistency 
of the budesonide and nedocromil effects across 
subgroups.
We used chi-square tests for categorical vari-
ables and t-tests for continuous variables to as-
sess differences in baseline characteristics be-
tween participants for whom data regarding 
adult height were missing and those for whom 
such data were available. We used logistic-regres-
sion analysis to check for systematic differences 
between participants with adult-height data and 
those without such data with respect to study-
group distribution in subgroups, as defined by 
the baseline covariates. Effects of missing data 
on adult height were further addressed in sensi-
tivity analyses with the use of two alternative 
methods to impute missing adult height. In the 
first method, we used a single imputation of 
adult height on the basis of bone age obtained at 
the end of the trial and the equations of Tanner 
et al.2,19 In the second method, we used multi-
variate multiple imputation with 13 imputations 
from simulations of a Bayesian posterior predic-
tive distribution of the missing data, using an 
iterative Markov chain Monte Carlo method based 
on the multivariate normal distribution provided 
by Stata software.23 All eight covariates in the 
model for difference in adult height were used 
together with serial height measurements ob-
tained 2 to 102 months after trial entry. The miss-
ing adult height data were assumed to be missing 
completely at random. Additional sensitivity analy-
ses were performed with the use of seven alter-
native definitions of adult height.
We used a linear regression model of height 
in relation to age, using all available age–height 
pairs for each participant in each 1-year age 
span, to determine age-specific growth velocity 
for each participant during the first 2 years of 
the trial. We assessed study-group differences in 
growth-velocity trends for participants between 
the ages of 5 and 15 years separately for each sex 
by means of a repeated-measures multiple linear 
regression model,24 including an indicator vari-
able for treatment, splines for each year of age, 
and interaction terms for treatment according to 
age. This analysis was also adjusted for the co-
variates used in the models of adult height. The 
significance of study-group differences in veloc-
ity trends was determined on the basis of the 
P value from an F-test of the simultaneous null 
effects of the study-group indicator and all age 
splines according to treatment interaction terms. 
We performed a secondary analysis of adult height 
in relation to the mean weight-adjusted dose of 
daily inhaled glucocorticoids (in micrograms per 
kilogram of body weight) during the first 2 years 
of the trial, with adjustment for demographic 
characteristics, status with respect to exposure 
to cigarette smoke in utero, and total prednisone 
dose throughout follow-up until adult height 
was attained, as well as asthma features, physi-
cal development, and vitamin D sufficiency or 
insufficiency at trial entry. The dose of inhaled 
glucocorticoids and weight were assumed to be 
constant over each reporting interval.
A two-sided P value of less than 0.05 was con-
sidered to indicate statistical significance, except 
in interaction analyses, for which a P value of 
less than 0.01 was considered to indicate signifi-
cance. Statistical analyses were performed with 
The New England Journal of Medicine 
Downloaded from nejm.org at WASHINGTON UNIV SCH MED MEDICAL LIB on April 16, 2014. For personal use only. No other uses without permission. 
 Copyright © 2012 Massachusetts Medical Society. All rights reserved. 
Effect of Inhaled Glucocorticoids on Adult Height
n engl j med 367;10 nejm.org september 6, 2012 907
the use of Stata software, version 12 (StataCorp) 
or SAS software, version 9.2 (SAS Institute).
R esult s
Adult Height
We obtained measurements of adult height for 
943 of the original 1041 CAMP participants 
(90.6%). Of these measurements, 96.8% were ob-
tained from women who were at least 18 years of 
age or men who were at least 20 years of age; 
3.2% of measurements were the most recently 
obtained heights that were less than 1 cm greater 
than a height obtained at least 1 year previously 
(Fig. 1). Adult height was not known for 98 par-
ticipants (9.4%): 35 female participants with a 
median age of 12 years (range, 8 to 17) and 63 
male participants with a median age of 14 years 
(range, 7 to 19) at the last height measurement.
The adjusted mean adult height was 1.2 cm 
lower in the budesonide group than in the pla-
cebo group (171.1 cm vs. 172.3 cm, P = 0.001); 
the mean adult height in the nedocromil group 
(172.1 cm) was similar to that in the placebo 
group (P = 0.61) (Table 1 and Fig. 2).25 The deficit 
in adult height in the budesonide group, as com-
pared with the placebo group, was greater for 
women (−1.8 cm, P = 0.001) than for men (−0.8, 
P = 0.10), but the effect of budesonide on adult 
height did not vary significantly according to sex 
(P = 0.10 for interaction) (Table 1). Although the 
deficit was greater for participants who were 
younger at trial entry than for those who were 
older and greater for whites than for those of 
other races or ethnic groups, the effect of 
budesonide on adult height did not vary signifi-
cantly according to the age at trial entry (P = 0.12 
for interaction), race or ethnic group (P = 0.50 for 
interaction), or duration of asthma at trial entry 
(P = 0.35 for interaction) (Table 1, and Table S1 
in the Supplementary Appendix). The deficit in the 
adjusted mean height in the budesonide group, 
as compared with the placebo group, was 1.3 cm 
(95% confidence interval [CI], −1.7 to −0.9) after 
1041 Underwent randomization
2093 Patients were assessed for eligibility
1052 Were excluded owing
to asthma that was too severe
or too mild, other reasons for 
ineligibility, nonadherence during
run-in period, or lack of interest
311 Were assigned to receive
budesonide
418 Were assigned to receive
placebo
312 Were assigned to receive
nedocromil
30 Were lost to follow-up 41 Were lost to follow-up27 Were lost to follow-up
281 Had measurement of adult height
271 Had measurement at age
       ≥18 yr (women) or
       ≥20 yr (men)
10 Grew <1 cm per year
377 Had measurement of adult height
368 Had measurement at age
≥18 yr (women) or
≥20 yr (men)
9 Grew <1 cm per year
285 Had measurement of adult height
274 Had measurement at age
≥18 yr (women) or
≥20 yr (men)
11 Grew <1 cm per year
Figure 1. Enrollment and Outcomes.
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2 years of treatment and 1.2 cm (95% CI, −2.0 to 
−0.4) at the end of the CAMP trial and persisted 
into adulthood without progressing further (−1.2 
cm; 95% CI, −1.9 to −0.5) (Fig. 2B).
Growth Velocity
Overall, age trends with respect to growth veloc-
ity in the budesonide and placebo groups differed 
during the first 2 years of the trial for women 
(P = 0.007) and men (P<0.001) (Fig. S2 in the Sup-
plementary Appendix). For both sexes, the differ-
ence in velocity reduction that was seen in the first 
2 years of assigned treatment in the budesonide 
group, as compared with the placebo group, was 
primarily among prepubertal participants (girls 
5 to 10 years of age, P = 0.001; girls 11 to 15 years 
of age, P = 0.54; boys 5 to 11 years of age, P<0.001; 
and boys 12 to 15 years of age, P = 0.57).
Sensitivity Analyses
In sensitivity analyses performed to assess the 
potential effect of missing adult heights, the re-
duction in adult height in the budesonide group 
as compared with the placebo group was also cal-
culated with imputation of missing adult heights 
based on bone age at the end of the trial19 (−1.1 cm, 
P = 0.004) and multivariate multiple imputation 
(−1.2 cm, P = 0.002). The between-group differ-
ence in adjusted mean adult height remained nu-
merically similar to that in the primary analysis 
and significant for all seven alternative defini-
tions of adult height (Table 2).
At trial entry, data for participants for whom 
measurements of adult height were not available 
were similar to data for those with available mea-
surements, except for the variable of the clinic site 
(P = 0.002) (Table S2 in the Supplementary Appen-
dix). There was no interaction between the study 
group and any of the baseline covariates, sug-
gesting that the study-group comparison among 
the 943 participants with known adult height 
may reasonably be generalized to the entire 
CAMP population.
Effects of Glucocorticoid Dose
During the trial period of 4 to 6 years, the mean 
adjusted total doses of inhaled glucocorticoids were 
636.1 mg in the budesonide group and 88.5 mg 
in the nedocromil group versus 109.4 mg in the 
placebo group (P<0.001 and P = 0.14, respective-
ly). During follow-up after the trial ended, the 
mean adjusted total doses were 381.0 mg in the 
budesonide group and 347.9 mg in the nedocro-
mil group versus 355.0 mg in the placebo group 
(P = 0.55 and P = 0.87, respectively).
The as-treated secondary analysis of the daily 
weight-adjusted dose of inhaled glucocorticoids 
during the first 2 years of the CAMP trial showed 
that a larger daily dose was associated with a 
lower adult height (−0.1 cm for each microgram 
per kilogram, P = 0.007). In addition, lower adult 
height was associated with Hispanic ethnic group 
(P<0.001) and female sex (P<0.001), as well as 
a higher Tanner stage (P<0.001), lower height 
Table 1. Adjusted Mean Adult Height among 943 Study Participants.*








Placebo (95% CI) P Value
Nedocromil vs. 
Placebo (95% CI) P Value
cm cm cm
All participants 171.1 172.1 172.3 −1.2 (−1.9 to −0.5) 0.001 −0.2 (−0.9 to 0.5) 0.61
Sex
Female 162.8 163.9 164.6 −1.8 (−2.9 to −0.7) 0.001 −0.7 (−1.8 to 0.5) 0.26
Male 176.8 177.6 177.6 −0.8 (−1.8 to 0.2) 0.10 −0.0 (−0.9 to 0.9) 0.98
P value for interaction 0.10 0.49
Age at entry
5–8 yr 170.7 171.8 172.6 −1.9 (−3.2 to −0.6) 0.004 −0.8 (−2.1 to 0.5) 0.22
9–13 yr 171.4 172.4 171.9 −0.5 (−1.7 to 0.6) 0.37 0.5 (−0.8 to 1.6) 0.48
P value for interaction 0.12 0.15
* Mean values for adult height have been adjusted for age, race or ethnic group, sex, clinic, duration of asthma, asthma severity, presence or 
absence of skin-test reactivity, and height at trial entry. In the analysis of mean adult height according to sex, 385 participants were female 
and 558 were male. In the analysis of age at study entry, 489 participants were 5 to 8 years of age and 454 were 9 to 13 years of age.
The New England Journal of Medicine 
Downloaded from nejm.org at WASHINGTON UNIV SCH MED MEDICAL LIB on April 16, 2014. For personal use only. No other uses without permission. 
 Copyright © 2012 Massachusetts Medical Society. All rights reserved. 
Effect of Inhaled Glucocorticoids on Adult Height
n engl j med 367;10 nejm.org september 6, 2012 909
(P<0.001), greater body-mass index (P<0.001), lon-
ger duration of asthma (P<0.001), skin-test reactiv-
ity (P<0.001), and vitamin D insufficiency (≤30 ng 
per milliliter, P = 0.004) at baseline. The cumulative 
prednisone dose from trial entry until attainment 
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B Height Difference, Budesonide vs. Placebo

















































Figure 2. Effect of Budesonide on Adult Height.
Panel A shows Tukey’s box plots of unadjusted height distribution at trial entry (at the age of 5 to 13 years), at 2 years, 
at the end of the trial, and at the time of adult-height determination for up to 311 participants receiving budesonide 
and 418 receiving placebo, according to sex. The bottom and top of each box are the 25th and 75th percentiles of 
the height distribution, respectively, and the horizontal line within the box is the median. The I bars indicate the 
range of the distribution that is not extreme (i.e., within 1.5 interquartile ranges of the 25th and 75th percentiles of 
the distribution), and the open circles show the extreme values in the height distribution. Panel B shows the adjusted 
mean difference in height between the budesonide group and the placebo group during follow-up. The I bars indicate 
95% confidence intervals. Means have been adjusted for age, race or ethnic group, sex, clinic, asthma severity, asthma 
duration, and presence or absence of skin-test reactivity at trial entry. Mean values for times after time 0 (trial entry) 
have also been adjusted for height at trial entry.
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Discussion
In an intention-to-treat analysis of the growth-
suppressive effect of long-term inhaled glucocor-
ticoid therapy for asthma initiated in children 
between the ages of 5 and 13 years, we found 
that the height deficit observed at 1 to 2 years 
after treatment initiation persisted into adult-
hood, although the deficit was neither progres-
sive nor cumulative. Our conclusion is based on a 
randomized comparison of adult height, with 
height data available for 91% of the CAMP co-
hort, with the use of recognized definitions of 
adult height,18-21 and with consistent findings in 
sensitivity analyses using imputation strategies 
for missing data and alternative definitions of 
adult height (Table 2). We found little evidence 
that the 98 participants for whom data regarding 
adult height were missing differed at trial entry 
from the 943 participants with available data 
(Table S2 in the Supplementary Appendix).
In contrast, the only other prospective longi-
tudinal cohort study that followed patients into 
adulthood11 was an open-label study, and by the 
time the patients reached adulthood, only 15 of 
the original controls were available, so the inves-
tigators recruited 51 healthy siblings of the pa-
tients with asthma to be controls. The investiga-
tors in that study based their conclusion of a lack 
of long-term effect on height on the finding that 
both controls and participants receiving budes o-
nide attained predicted adult height rather than 
on a randomized comparison of the adult heights 
reached by the two groups.
The growth-velocity deficit that we observed 
in the budesonide group, as compared with the 
placebo group, during the first 2 years of treat-
ment was primarily among prepubertal children 
(Fig. S2 in the Supplementary Appendix). Our 
ability to further disentangle the effects of dura-
tion of treatment, age at treatment, and puberty 
status during treatment on growth velocity was 
limited because of confounding. Nevertheless, 
the effect on adult height of budesonide as com-
pared with placebo was clearly demonstrated in 
the CAMP population.
Two previous 1-year studies of beclomethasone 
dipropionate also showed a greater reduction in 
growth in prepubertal children than in pubertal 
children.26,27 Like other studies in which prepu-
bertal children received different doses of the 
same inhaled glucocorticoids that have shown a 
dose–response effect on growth,28,29 our study 
showed a weight-based, dose-dependent effect in 
the CAMP participants (Table S3 in the Supple-
mentary Appendix).
We found that a longer time since asthma di-
agnosis at trial entry and atopy (any positive skin 
test) were independent risk factors for shorter adult 
height (Table S3 in the Supplementary Appendix). 
Other investigators have reported an increased in-
cidence of short stature in children with atopy and 
asthma.30-32 One of these studies31 showed that 
short stature was associated with an early onset 
of asthma (before the age of 3 years), a finding 
that is consistent with our data. However, atopy-
induced growth retardation has been associated 
with a delay in bone maturation and thus was 
thought to be unlikely to affect adult height.32,33 
Our results suggest that when asthma and atopy 
impair growth, the deficit may persist into 
adulthood.
We selected a daily dose of 400 μg of budeso-
nide for the CAMP trial to ensure a therapeutic 
effect in both children with mild asthma and 
those with moderate asthma.2 Since then it has 
been shown that daily administration of 200 μg of 
budesonide by means of a dry-powder inhaler ef-
fectively controls asthma symptoms and reduces 
exacerbations in children 5 to 11 years of age.3 
Even at this lower dose, there was a reported mean 
reduction of 1.0 cm in height during the first 
2 years of therapy.3 Although the systemic effects 
of inhaled glucocorticoids are dose-dependent, 
they are also dependent on the therapeutic index 
of the specific inhaled glucocorticoid and the 
delivery device used.4-9 Thus, it seems prudent to 
select inhaled glucocorticoids and devices with 
higher therapeutic indexes and to use them in the 
lowest effective doses in children with persistent 
asthma.1,9
In conclusion, the reduction in growth seen in 
the first few years of administration of inhaled 
glucocorticoids in prepubertal children persists 
as lowered adult height. However, in the infor-
mation about inhaled glucocorticoids and their 
side effects that is provided to parents, the po-
tential effect on adult height must be balanced 
against the large and well-established benefit of 
these drugs in controlling persistent asthma. It 
is appropriate to use the lowest effective dose for 
symptom control in order to minimize concern 
about the effects of inhaled glucocorticoids on 
adult height.
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